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The activity of a large variety of genes determines the biological
behaviour of an individual tumour. Because cancer can be defined
as the unscheduled accumulation of cells, genes controlling
growth and proliferation must be critically involved in this disease
process. However, proliferation is numerically balanced by cell
death in normal tissue homeostasis and only recently has deranged
cell death control evolved as an important keyplayer in the patho-
genesis of cancer (Fisher, 1994). Systematic studies on parameters
of cell loss in human tumour samples are scarce to date.
Cells normally die by apoptosis in the healthy organism
(Jacobson et al, 1997; Nagata, 1997). Apoptosis is a genetically
encoded cell death programme defined by characteristic morpho-
logical and biochemical changes which reflect the fact that normal
cell death must proceed without afflicting damage to neighbouring
cells. Various hierarchy levels of genes are involved in the control
of cell death. Sensors such as the tumour suppressor p53 can
trigger apoptosis as a reaction to unfavourable conditions, such as
DNA-damaging drugs or hypoxia. More downstream, the inter-
play of different Bcl-2 family members determines whether apop-
tosis is allowed to proceed or not. At the executive end of this
hierarchy, a whole cascade of caspases is involved in effecting the
typical morphological changes of apoptosis. The interplay of all
these gene products and other factors determines the threshold for
the induction of apoptosis in an individual cell (Fisher, 1994).
Among the regulators of cell death, Bcl-2 (B-cell lymphoma/
leukaemia 2) stands out for its evolutionary conservation and its
ability to regulate a very downstream step of the cell death
pathway (Nagata, 1997; Reed, 1997). High levels of Bcl-2 protein
can protect cancer cells from apoptotic cell death induced by a
wide variety of stimuli and insults, including radiation and chemo-
therapeutic drugs. The discovery of genes encoding proteins with
significant amino acid sequence homology has led to the
expanding family of Bcl-2-related genes (Reed, 1997). The
composition or ratio of the different Bcl-2 family members may
play an important role in the pathogenesis of cancer and determine
the chemosensitivity in an individual tumour. The molecular
details of these interactions are not fully understood. Some of the
Bcl-2 family members such as Mcl-1 (myeloid cell leukaemia 1)
seem to block cell death, whereas others such as Bax or Bak abro-
gate Bcl-2 function and promote cell death (Reed, 1997). With the
exception of Bcl-2, little is known about the expression of the
different Bcl-2 family members in human cancer at present.
Mutations of the p53 tumour-suppressor gene belong to the most
frequent gene alterations in solid tumours (Harris, 1996). Loss of
p53 function may partly explain their notorious chemo- and radio-
therapy resistance because DNA damage cannot be sensed and
translated into apoptosis (Fisher, 1994; Borner et al, 1995; Kinzler
and Vogelstein, 1996). In addition, p53 mutations can also lead to
gain-of-function conferring increased tumorigenicity, proliferative
capacity, metastatic potential and tissue invasiveness (Harris, 1996).
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Summary Proteins of the Bcl-2 family as well as p53 are important regulators of apoptosis. Alterations in the expression of these proteins can
contribute to the formation of cancer, as well as influence tumour response to chemo- and radiotherapy. We used antibodies specific for the
human Bcl-2, Mcl-1, Bax, Bak and p53 proteins to examine the expression of these apoptosis-regulating genes in 49 archival specimens of
patients with radically resected non-small-cell lung cancer (NSCLC). Tumour cells containing immunostaining for the antiapoptotic proteins
Bcl-2 and Mcl-1 were present in 31% and 58% of the cases evaluated, respectively, whereas immunopositivity for the proapoptotic proteins
Bax and Bak was found in 47% and 58% of the samples. p53 immunopositivity was detected in 61% of the samples. The expression of Bcl-2
and p53 and the expression of Mcl-1 and Bax showed a positive association (P = 0.02 and P = 0.06 respectively), whereas the expression of
Bax was inversely related to p53 (P = 0.008). The expression of Bcl-2 had a negative influence on relapse-free survival in this population of
primary resected NSCLC patients (P = 0.02). The expression of p53 and Bcl-2 was significantly associated with metastasis-free survival
(P < 0.01). Only patients with p53-positive tumours developed metastases during the follow-up period. Our results establish the frequent
expression of the Bcl-2 family proteins Bcl-2, Mcl-1, Bax and Bak in NSCLC. It can be expected that Bcl-2 family members have no
straightforward impact on clinical outcome in this disease because their interactions in the regulation of apoptosis are complex.
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Lung cancer is the leading cause of cancer death in Europe and the
USA (Boring et al, 1994). More than 150 000 new cases are diag-
nosed in Europe every year, but less than 10% of these patients can
be cured. Eighty per cent of malignant lung tumours are non-small-
cell lung cancer (NSCLC). Despite wide surgical excision, metas-
tases and local relapse are frequent after resection of early stage
NSCLC. This makes the availability of prognostic factors for these
events highly desirable to guide the use of (neo)adjuvant treatment
modalities and to aid the decision about the extent of the operative
procedure. The present study examined the differential expression
pattern and the prognostic significance of the Bcl-2 family members
Bcl-2, Mcl-1, Bax and Bak and of p53 in primary resected NSCLC.
PATIENTS AND METHODS
Patient features
Tumour samples were obtained from 49 consecutive patients
(three women, 46 men) who underwent complete surgical resec-
tion for NSCLC at the Division of Thoracic Surgery of the
University Hospital of Bern, Switzerland.
Immunohistochemistry
Paraffin-embedded tumour specimens that had been fixed in neutral-
buffered formalin were sectioned (4 mm) and immunostained using
anti-peptide polyclonal antisera specific for Mcl-1 (1 : 800),
Bax (1 : 2000) and Bak (1 : 1000), as previously described in detail
(Krajewska et al, 1996). The specificity of all these antibody reagents
had been demonstrated based on comparisons with preimmune
serum, peptide competition experiments, and immunoblot analyses
of tissue extracts and cell lines (Krajewska et al, 1996). Monoclonal
antibodies (both from Dako, Glostrop, Denmark) were used
for p53 (M 7001, Dako-p53, DO-7; 1 : 50) and for Bcl-2 (MO 887,
Dako-Bcl-2, 124; 1 : 50). Immunodetection was achieved by an
avidin–biotin horseradish-peroxidase-based colourimetric method
using 3,3¢-diaminobenzidine as the chromogen, followed by light
counterstaining with haematoxylin. The slides were assessed for each
antibody by two reviewers unaware of patients characteristics and
outcome. Specimens were considered immunopositive when > 50%
of the tumour cells had clear evidence of immunostaining. Negative
controls were processed by exclusion of the primary antibody. The
positive internal controls are described in the Results section.
Statistical analyses
Association of immunostaining results (p53, Bcl-2, Mcl-1, Bax,
Bak) with other categorical features (tumour histology, stage,
differentiation, lymphocytic infiltration, necrosis, smoking
history) was tested using the Fisher’s Exact test. Actuarial relapse-
free survival rates were calculated from the date of the definitive
tumour operation to local relapse or the occurrence of metastases.
Complete follow-up information was available in 47 patients.
Kaplan–Meier estimates were used for relapse-free distributions
(Kaplan and Meier, 1958). Differences between groups were
evaluated with the log-rank test. All tests were two-sided.
RESULTS
A total of 49 samples of primary resected NSCLC were processed
for p53, Bcl-2, Mcl-1, Bax and Bak expression by immunohisto-
chemistry. Table 1 lists the frequency of positivity for the various
markers. The immunostaining for p53 was nuclear (Figure 1A),
whereas staining for Bcl-2 family proteins was typically cyto-
plasmic, because these proteins are usually associated with
cytosolic organelles such as mitochondria and endoplasmatic
reticulum. Mcl-1 and Bak also showed nuclear reactivity, which is
in keeping with the possible interaction of Bcl-2 family proteins
with the nuclear membrane (Reed, 1997). Patient and tumour
characteristics are listed in Table 2. In our series, a relatively high
proportion of patients with squamous cell carcinomas was present.
Most patients were men and the median age of the study popula-
tion was 64 (range 45–79) years. Additional characteristics of this
series have been described before (Betticher et al, 1996).
Table 1 Immunohistochemical analysis of the NSCLC tumour samples with
antibodies against human p53, Bcl-2, Mcl-1, Bax and Bak
p53 Bcl-2 Mcl-1 Bax Bak
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––+ + +
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+–+ + +
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Analysis of protein expression and clinical features
p53
The monoclonal antibody DO-7 specifically detects the wild-type
and mutant forms of human p53. Positive immunostaining for p53
suggests mutant p53 because normal p53 is virtually undetectable
by antibody-mediated staining owing to its rapid degradation
(Harris, 1996). Immunoreactivity for p53 was found in 61% of the
tumours (Figure 1A), which compares well with other descriptions
in the literature (Apolinario et al, 1997). There was significant
positive association of p53 and Bcl-2 expression (P = 0.02,
Fisher’s exact test; Table 3A), whereas p53 and Bax were
inversely related (P = 0.008; Table 3B). There was no association
of p53 expression with any of the clinicopathological features
listed in Table 1. However, patients with p53 overexpression were
more likely to have a history of smoking (P = 0.05, Fisher’s exact
test; Table 3C).
Bcl-2
Immunoreactivity for Bcl-2 was found in 31% of the tumours
(Figure 1C). The basal layers of the bronchial epithelium or mantle
zone lymphocytes (Figure 1D), in which normal to strong intensity
Bcl-2 immunostaining was typically seen (Pezzella et al, 1993),
served as a positive control. Except for p53 (see above), there was
no significant correlation between Bcl-2 accumulation and the
A
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Figure 1 Photomicrographs of representative examples of immunohistochemical staining of NSCLC with p53, Bcl-2, Mcl-1, Bax, and Bak. (A) Typical nuclear
p53 immunostaining in a stage I squamous cell carcinoma. Bcl-2 family proteins typically show cytoplasmic staining (B–F). (B) Mcl-1 immunoreactivity in tumour
cells of a stage III squamous cell carcinoma. (C) Focal Bcl-2 immunoreactivity in tumour cells of a stage I squamous cell carcinoma. (D) Bcl-2 immunoreactivity
of mantle zone lymphocytes as a positive internal control. Note the Bcl-2-negative germinal centre cells. (E) Bax immunoreactivity in tumour cells of a stage I
adenocarcinoma (F) Bak immunoreactivity in tumour cells of a stage I adenocarcinomaBcl-2 family members and p53 in lung cancer 955
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expression of any of the other oncoproteins of interest. Among the
other clinical and pathological variables, Bcl-2 expression was
significantly associated with necrotic features in the tumour
(P = 0.01, Fisher’s exact test; Table 3D).
Mcl-1
Immunoreactivity for Mcl-1 was found in 58% of the tumours
(Figure 1B). Chondrocytes and germinal centre lymphocytes were
used as positive internal control for Mcl-1 (Krajewski et al, 1995).
There was a trend for an association between Mcl-1 and Bax
expression (P = 0.06, Fisher’s exact test; Table 3E), but no correla-
tion between Mcl-1 and other clinicopathological parameters.
Bax
Immunoreactivity for Bax was found in 47% of the tumours
(Figure 1E). Interfollicular lymphocytes served as an internal posi-
tive control for Bax expression (Krajewski et al, 1994). Except for
the positive association with Mcl-1 and the negative association
with p53 expression (see above), there was no relation between
Bax expression and other clinicopathological parameters.
Bak
Immunoreactivity for Bak was found in 58% of the tumours
(Figure 1F). Smooth muscle cells of arteries served as an internal
positive control for Bak expression (Krajewski et al, 1996). There
was no correlation between Bak expression and other clinico-
pathological parameters.
Impact of oncoprotein expression on tumour relapse
Relapse-free survival was taken as outcome end point in this study
because too few events occurred to assess overall survival. During
the follow-up period, 18 out of 47 tumours (38%) have relapsed.
Table 4 describes the influence of the expression of the onco-
proteins under investigation on overall relapse-free survival and
progression-free survival according to relapse site. Thirteen out of
47 (28%) of the patients developed distant metastases and 13 out
of 47 (28%) had a local relapse. Seven (15%) of the patients had
concomitant local and distant progression. Bcl-2 expression
showed a negative association with overall relapse-free survival
and metastasis-free survival in this study population (log rank P =
0.02 and P < 0.01 respectively). The expression of p53 also had a
Table 2 Patient characteristics
Number of patients 49
Sex
Male 46
Female 3
Histology (WHO, 1981)
Squamous carcinoma 34
Adenocarcinoma 9
Large cell carcinoma 6
Tumour differentiation
Good–intermediate 31
Poor 18
Lymphocyte infiltration of the tumour
Poor 24
Moderate–important 25
Tumour necrosis
None–moderate 30
Important 19
Stage (UICC, 1987)
I2 7
II 3
III 19
Surgical intervention
Lobectomy 36
Pneumonectomy 13
Table 3 Two-sided tables for Fisher’s exact t-test calculations
A
Bcl-2 negative Bcl-2 positive
p53 negative 17 2
p53 positive 17 13
B
Bax negative Bax positive
p53 negative 5 13
p53 positive 20 9
C
Non-smoker Smoker
p53 negative 3 8
p53 positive 0 29
D
Necrosis (0–+) Necrosis (++–+++)
Bcl-2 negative 25 9
Bcl-2 positive 5 10
E
Mcl-1 negative Mcl-1 positive
Bax negative 15 10
Bax positive 4 18
Table 4 Influence of oncoprotein expression on progression-free survival
Marker Event Median survival Log-rank
(months) P-value
p53 +/– All 32/nr ns1
Local relapse nr/nr ns
Metastases 32/nr <0.01
Bcl-2 +/– All 8/32 0.02
Local relapse nr/nr ns
Metastases 8/nr <0.01
Mcl-1 +/– All nr/17 ns
Local relapse nr/23 ns
Metastases nr/nr ns
Bax +/– All 32/23 ns
Local relapse nr/23 ns
Metastases nr/nr ns
Bak +/– All 32/23 ns
Local relapse nr/23 ns
Metastases 32/nr ns
1 ns, not significant (P > 0.05).956 MM Borner et al
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striking impact on the occurrence of metastases because no
such event was observed in patients with p53-negative tumours
(P < 0.01; Figure 2).
DISCUSSION
We characterized here the expression of different members of the
Bcl-2 gene family in primary resected NSCLC. Mcl-1, Bak, Bax
and Bcl-2 were frequently expressed with 58%, 58%, 47%, and
31% of the tumours staining positive respectively. However, the
percentage of immunopositive tumour cells was highly variable,
implying a complex control of the production of these apoptosis-
regulating proteins and suggesting the possibility that their expres-
sion is a late event in the formation of NSCLC. At the protein level,
the various Bcl-2 family members can dimerize with one another,
with one monomer antagonizing or enhancing the function of the
other. In this way, the ratio of inhibitors to activators may deter-
mine the propensity of a cell to undergo apoptosis. With the excep-
tion of Bcl-2, relatively little is known about the expression of
other family members in human cancer. In a series of 64 prostate
cancer patients, Bax was expressed in all samples, whereas Mcl-1
expression was found in 81% and Bcl-2 in 25% of the cases
(Krajewska et al, 1996). In stomach cancer, the antiapoptotic
proteins Bcl-2 and Mcl-1 were present in 54% and 75% of the
cases evaluated, whereas the proapototic proteins Bax and Bak
were found in 92% and 88% of the specimens respectively
(Krajewska et al, 1996). In all three series, Bcl-2 has shown the
most restricted expression of all family members. Because one
function of Bcl-2 is to provide protection from apoptosis, these
results could be taken as evidence for a low apoptosis threshold of
these tumours. However, this is contradicted by their notorious
chemoresistance. Thus, it is possible that the role of Bcl-2 is redun-
dant and that other antiapoptotic members of the Bcl-2 family can
take over its function, as suggested by the reciprocal pattern of Bcl-
2 and Mcl-1 expression in normal tissues (Krajewski et al, 1995).
Because transformation per se seems to lower the apoptosis
threshold, apoptosis-suppressing activity could be a requirement
for the occurrence of cancer (Fisher, 1994). We found that the
expression of Mcl-1 and Bax was positively correlated in our
NSCLC samples. A similar pattern has been found in
Reed–Sternberg cells of Hodgkin’s disease, suggesting that Bcl-2
or other family members such as Mcl-1 may neutralize the cell
death-promoting activity of Bax allowing for malignant cell
survival (Brousset et al, 1996). Until more details are known about
the regulation of the expression and the interaction of these
proteins, it is difficult to judge on the significance of these findings.
The prognostic role of Bcl-2 in NSCLC is controversial. Studies
in patients with NSCLC have demonstrated that Bcl-2 expression
is associated with favourable prognosis (Pezzella et al, 1993;
Fontanini et al, 1995). This finding is against mainstream thinking
because the antiapoptotic action of Bcl-2 is expected to confer a
survival advantage to the cancer cell. Bcl-2 has recently been
shown to suppress the proliferative activity of cells, which could
explain the less aggressive biology of Bcl-2-positive tumours
(Borner, 1996). However, Pastorino et al (1997) did not find Bcl-2
serving as a prognostic factor for overall survival in their series of
patients with stage I lung cancer. Although patients with Bcl-2-
positive tumours had a better prognosis in their univariate analysis
for time to recurrence, this factor dropped out in the multivariate
analysis of this large series of 515 cases. Brambilla et al (1996)
examined Bcl-2 expression in 121 neuroendocrine lung tumours
and found a shortened survival in patients with Bcl-2-positive
tumours. These results underline the fact that different Bcl-2
family proteins and other factors contribute to the biology of an
individual tumour, and that it may therefore not be possible to
extract reliable prognostic significance from the analysis of a
single member of the Bcl-2 protein family.
Unexpectedly in the context of the putative cell-death-
suppressing role of Bcl-2, we found that Bcl-2-positive tumours
exhibit more necrosis than Bcl-2-negative tumours. This confirms
the trend described in the paper by Tormanen et al (1995), in which
tumour necrosis, but not apoptosis, seemed to correlate with Bcl-2
positivity in NSCLC tumours. However, the same authors have
found a positive association between the extent of apoptosis and
Bcl-2 immunoreactivity in small-cell lung cancer (Eerola et al,
1997). These results suggest independent regulatory pathways of
apoptosis and necrosis in lung cancer, and could also partially
reflect the inherent methodological problems in identifying and
quantifying apoptotic cells in tumour samples [Potten et al, 1996].
In addition, considering the various possible consequences of Bcl-
2 activity on cell cycle and cell death, it will be difficult to predict
the prognostic impact of Bcl-2 expression in solid tumours.
Another key player for the role of apoptosis in the pathogenesis
and treatment of cancer is the p53 tumour-suppressor gene.
Abnormalities of p53 function are among the most frequently
identified genetic alterations in human neoplasms, including lung
carcinoma (Hollstein et al, 1991; Harris and Hollstein, 1993). p53
overexpression was present in 61% of our samples, which is in
agreement with most of the published series (Chiba et al, 1990;
Apolinario et al, 1997). Of all the clinicopathological features, we
found p53 only to be correlated with a positive smoking history.
Smoking has been described as favouring GC to AT transitions in
the p53 gene in squamous cell carcinomas of the lung (Liloglou et
al, 1997).
The relationship between p53 expression and prognosis in
NSCLC is controversial. Nuclear p53 expression has been linked
to poor prognosis (Quinlan et al, 1992; Fujino et al, 1995; Harpole
et al, 1995), better prognosis (Lee et al, 1995), or no difference at
all (Brambilla et al, 1993; Pastorino et al, 1997). These controver-
sial results are difficult to interpret. Possible variables among the
series were the use of different antibodies and methods, different
fixation procedures, and different cut-off values. In addition, the
correlation between p53 sequence and nuclear accumulation of
p53 protein is indirect. Lack of accumulation may be a result of the
type of mutation, such as nonsense mutations, and the presence of
1.0
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0
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Months
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Figure 2 Metastasis-free survival by p53accumulation may be for reasons other than mutations, which
increase the half-life of p53 protein. We found a highly significant
impact of p53 expression on the risk of metastatic recurrence, but
not on the occurrence of local relapse. Because loss of p53 func-
tion helps cells to adapt to adverse conditions in the microenviron-
ment, p53 mutations might confer a survival advantage to
micrometastases at distant organ sites.
Aside from its interplay in the regulation of apoptosis, p53 has
been shown to directly affect Bcl-2 and Bax expression. Negative
response elements for wild-type p53, but not mutant p53, have
been found in the 5¢ untranslated regions of the Bcl-2 gene,
through which wild-type but not mutant p53 is able to mediate
repression of the Bcl-2 gene (Miyashita et al, 1994). In addition,
wild-type p53 was found to strongly transactivate the expression
of Bax, and p53 binding sites were also identified in the Bax
promoter [Miyashita and Reed, 1995]. This has led to the specula-
tion that Bax protein is one of the effectors of p53-induced apop-
tosis. We found a correlation of p53 positivity with Bcl-2
expression in our series. Because positive p53 immunostaining is
mostly due to mutations, the repression of Bcl-2 expression by p53
should be lifted in these cases. Although our finding is corrobo-
rated by others (Brambilla et al, 1996), an inverse relationship
between p53 and Bcl-2 expression has also been observed in
NSCLC (Silvestrini et al, 1994; Fontanini et al, 1995). At the func-
tional level, the significance of the positive association of p53 and
Bcl-2 is strengthened by the inversely correlated expression of p53
and Bax in our series.
To date, pathological staging remains the most reliable determi-
nant of prognosis in NSCLC, and the main factor in the choice of
curative treatment. However, it is of great interest to verify new
biological markers to define the risk of relapse or to decide on the
use of (neo)adjuvant treatment. In this context, our observation of
an association between the p53 and Bcl-2 status and the occur-
rence of distant metastases in NSCLC is of potential interest and
requires confirmation.
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